Compound 196
Identifiers
- Canonical SMILES:
CN1c2ncnn2[C@H](C2=C1c1ccccc1O[C@@H]2c1ccc(Br)cc1)c1ccc(C)cc1
- InChi:
InChI=1S/C26H21BrN4O/c1-16-7-9-17(10-8-16)23-22-24(30(2)26-28-15-29-31(23)26)20-5-3-4-6-21(20)32-25(22)18-11-13-19(27)14-12-18/h3-15,23,25H,1-2H3/t23-,25+/m0/s1
- InChiKey:
XTOOFJKUOMSKAG-UKILVPOCSA-N
External links
44549628 |
External search
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
MDM2-Like / P53 | 5.32 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 484.09 g/mol | |||
HBA | 5 | |||
HBD | 0 | |||
HBA + HBD | 5 | |||
AlogP | 6.25 | |||
TPSA | 43.18 | |||
RB | 2 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.4349 | BMS-394136 | DB12067 | |
0.3736 | GDC-0927 | DB14934 | |
0.3545 | LY-2881835 | DB15046 | |
0.3402 | Galicaftor | DB14894 | |
0.3387 | Cannabichromene | DB14735 | |
0.3386 | Parsaclisib | DB14867 | |
0.3374 | (4aS,6R,8aS)-11-[8-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)octyl]-6-hydroxy-3-methoxy-5,6,9,10-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-11-ium | DB02673 | |
0.3369 | Rocaglamide | DB15495 | |
0.3369 | Naldemedine | DB11691 | |
0.3358 | LY-518674 | DB12988 | |
0.3356 | Iclaprim | DB06358 | |
0.3356 | (S)-iclaprim | DB07938 | |
0.3356 | 5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl]pyrimidine-2,4-diamine | DB08741 | |
0.3343 | MK-1775 | DB11740 | |
0.3333 | Lavoltidine | DB12884 |